5’UTR point substitutions and N-terminal truncating mutations of ANKRD26 in acute myeloid leukemia
Authors:
- Caterina MarconiCMCaterina Marconi
- Ilaria CanobbioICIlaria Canobbio
- Valeria BozziVBValeria Bozzi
- Tommaso PippucciTPTommaso Pippucci
- Giorgia SimonettiGSGiorgia Simonetti
- Federica MelazziniFMFederica Melazzini
- Silvia AngoriSASilvia Angori
- Giovanni MartinelliGiovanni Martinelli
- Giuseppe SaglioGSGiuseppe Saglio
- Mauro TortiMTMauro Torti
- Ira PastanIra Pastan
- Marco SeriMSMarco Seri
Open Access
- 18 January 2017
- journal article
- research article
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 10 (1) , 1-4
Abstract
Thrombocytopenia 2 (THC2) is an inherited disorder caused by monoallelic single nucleotide substitutions in the 5’UTR of the ANKRD26 gene. Patients have thrombocytopenia and increased risk of myeloid malignancies, in particular, acute myeloid leukemia (AML). Given the association of variants in the ANKRD26 5’UTR with myeloid neoplasms, we investigated whether, and to what extent, mutations in this region contribute to apparently sporadic AML. To this end, we studied 250 consecutive, non-familial, adult AML patients and screened the first exon of ANKRD26 including the 5’UTR. We found variants in four patients. One patient had the c.−125T>G substitution in the 5’UTR, while three patients carried two different variants in the 5’ end of the ANKRD26 coding region (c.3G>A or c.105C>G). Review of medical history showed that the patient carrying the c.−125T>G was actually affected by typical but unrecognized THC2, highlighting that some apparently sporadic AML cases represent the evolution of a well-characterized familial predisposition disorder. As regards the c.3G>A and the c.105C>G, we found that both variants result in the synthesis of N-terminal truncated ANKRD26 isoforms, which are stable and functional in cells, in particular, have a strong ability to activate the MAPK/ERK signaling pathway. Moreover, investigation of one patient with the c.3G>A showed that mutation was associated with strong ANKRD26 overexpression in vivo, which is the proposed mechanism for predisposition to AML in THC2 patients. These data provide evidence that N-terminal ANKRD26 truncating mutations play a potential pathogenetic role in AML. Recognition of AML patients with germline ANKRD26 pathogenetic variants is mandatory for selection of donors for bone marrow transplantation.Keywords
Funding Information
- Fondazione Telethon (GGP10089)
- Fondazione Cariplo (2012-0529)
- Fondazione Cariplo (2010-0807)
- Ministero della Salute (RF-2010-2310098)
- National Cancer Institute (intramural)
This publication has 10 references indexed in Scilit:
- Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived MalignancyTransplantation and Cellular Therapy, 2016
- How I diagnose and manage individuals at risk for inherited myeloid malignanciesBlood, 2016
- Correspondence Regarding the Consensus Statement from the Worldwide Network for Blood and Marrow Transplantation Standing Committee on Donor IssuesTransplantation and Cellular Therapy, 2016
- Acute Myeloid LeukemiaNew England Journal of Medicine, 2015
- Thrombocytopenia-associated mutations in the ANKRD26 regulatory region induce MAPK hyperactivationJournal of Clinical Investigation, 2014
- ANKRD26-related thrombocytopenia and myeloid malignanciesBlood, 2013
- Ankrd26 Gene Disruption Enhances Adipogenesis of Mouse Embryonic FibroblastsJournal of Biological Chemistry, 2011
- Mutations in ANKRD26 are responsible for a frequent form of inherited thrombocytopenia: analysis of 78 patients from 21 familiesBlood, 2011
- Mutations in the 5′ UTR of ANKRD26, the Ankirin Repeat Domain 26 Gene, Cause an Autosomal-Dominant Form of Inherited Thrombocytopenia, THC2The American Journal of Human Genetics, 2011
- A novel CBFA2 single-nucleotide mutation in familial platelet disorder with propensity to develop myeloid malignanciesBlood, 2001